IVRs comprising a silicone matrix that releases the ARV drug dapivirine, over one month is the only microbicide evaluated in a phase III clinical trial demonstrating efficacy (27 and 31%) in preventing HIV transmission in women as determined in The Ring Study and ASPIRE studies (11, 12). The dapivirine ring is currently being evaluated in parallel open-label studies (DREAM and HOPE) led by the International Partnership for Microbicides (IPM) and the US National Institutes of Health-funded Microbicides Trials Network (MTN) and is under regulatory review.
- Epidemiology & Natural History
- Virology & Immunology
- Diagnostic & Monitoring Tests
- Primary HIV infection
- HIV-infectious Disease & Cancer
- Respiratory tract infections in patients with HIV infection
- Tuberculosis
- Non-tuberculous mycobacterial infections in people with HIV infection
- Opportunistic infections of the gastrointestinal tract
- Ocular disease in patients with HIV infection
- Opportunistic infections acquired in localised geographical regions of the world
- Human papillomavirus-associated malignancy
- Skin disease
- Opportunistic infections of the nervous system (coming soon)
- Malignant and lymphoproliferative conditions complicating HIV infection (coming soon)
- Opportunistic infections and cancers of the mouth and oropharynx (coming soon)
- Other HIV-Associated Disease
- Co-infections
- ARV Drugs & other Therapies
- Antiretroviral drugs
- Initiation of antiretroviral therapy in treatment-naïve people
- Long-term management of antiretroviral therapy
- Antiretroviral therapy guidelines
- Immune reconstitution inflammatory syndrome and other immune reconstitution disorders
- Prevention of opportunistic infections with antimicrobial therapy (coming soon)
- Drug-drug interactions in patients with HIV infection
- Adverse reactions to antiretroviral and other drugs in people with HIV infection
- Vaccines in people with HIV infection
- Co-Morbidities
- Special Patient Populations
- Biomedical prevention
- Nurses & Midwives
- New HIV Diagnosis
- Late presentation of new HIV diagnosis
- Partner notification and contact tracing
- Key Affected Populations
- Pregnancy and midwifery considerations in HIV
- Paediatric issues
- Client education
- Nursing considerations of major clinical issues
- HIV-associated neurocognitive disorder
- Adherence support
- Health promotion
- Clinical supervision for nurses in the HIV sector
- Biomedical HIV prevention
- Evolving roles of nurses in HIV care
- Nursing ethics in the care of people with HIV
